ArticleNature communications2020
Inhibitors of BRAF dimers using an allosteric site.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 81 citations in OpenAlex.
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Tyrosine kinases sample unique activation ensembles.bioRxiv : the preprint server for biology · 2026Article
- Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.ChemMedChem · 2026Article
- Electroacupuncture (EA) promotes angiogenesis and ameliorates dysregulated autophagy in ischemic stroke mice by modulating the ELAVL1/SIRT1/FOXO1 pathway.Metabolic brain disease · 2026Article
- MEK interactions tune RAF kinase sensitivity to conformation-selective inhibition.Nature chemical biology · 2026Article
- Ribosomal Protein RPL29 Promotes Hepatocellular Carcinoma Progression Through Regulation the Expression of Exosome Component 4.Biological procedures online · 2026Article
- A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma.Biomedicines · 2025Review
- Article
- Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors.Combinatorial chemistry & high throughput screening · 2025Article
- Prediction and Validation of Novel BRAF Inhibitor as a Potential Drug Candidate for the Treatment of Colorectal Cancer.Current topics in medicinal chemistry · 2025Article
- Profiling the expression and functional roles of mRNAs and lncRNAs associated with post-stroke aphasia.Frontiers in molecular neuroscience · 2025Article
- TargetingBiotechnologia · 2025Article
- ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding.The Biochemical journal · 2024Article
- BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells.International journal of molecular sciences · 2024Article
- Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells.Cell reports · 2024Article
- Multi-output prediction of dose-response curves enables drug repositioning and biomarker discovery.NPJ precision oncology · 2024Article
- Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Molecular oncology · 2024Review
- Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.eLife · 2024Article
- Targeting RAF dimers in RAS mutant tumors: From biology to clinic.Acta pharmaceutica Sinica. B · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Xiomaris M Cotto-Rios *Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-0922-1857
Bogos Agianian *Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA. bogos.agianian@einsteinmed.org.ORCID http://orcid.org/0000-0003-1295-6846
Nadege GitegoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Emmanouil ZacharioudakisDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Orsi GiriczDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID http://orcid.org/0000-0002-1328-3682
Yang WuDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Yiyu ZouDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Amit VermaDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Poulikos I PoulikakosDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
Evripidis GavathiotisDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA. evripidis.gavathiotis@einsteinmed.org.ORCID http://orcid.org/0000-0001-6319-8331
Albert Einstein College of Medicine · USIcahn School of Medicine at Mount Sinai · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MTraining in Aging ResearchT32AG023475 · NIA · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI NIR J BARZILAI, DEREK Major HUFFMAN · 2004 to 2026
$8.6MSmall Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7MAllosteric inhibitors targeting oncogenic BRAF V600E dimersR01CA238229 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GAVATHIOTIS, EVRIPIDIS · 2020 to 2024
$2.2MMechanism-based strategies to target oncogenic BRAF signalingR01CA204314 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI POULIKAKOS, POULIKOS I · 2017 to 2021
$2.1MNCI NIH HHS P30 CA013330NCI NIH HHS R01 CA178394NCI NIH HHS R01 CA204314NCI NIH HHS R01 CA238229NIA NIH HHS T32 AG023475
Abstract
BRAF kinase, a critical effector of the ERK signaling pathway, is hyperactivated in many cancers. Oncogenic BRAF
Indexed as
Allosteric SiteAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCrystallography, X-RayDrug DesignDrug Screening Assays, AntitumorHumansImidazolesMAP Kinase Signaling SystemMolecular Docking SimulationMutationNeoplasmsProtein Kinase InhibitorsProtein MultimerizationProtein SubunitsProto-Oncogene Proteins B-rafBRAF protein, humanImidazolesponatinibProtein Kinase InhibitorsProtein SubunitsProto-Oncogene Proteins B-rafPyridazinesSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.